Document Type

Article

Publication Date

2025

DOI

10.22034/mnba.2025.540837.1153

Publication Title

Micro Nano Bio Aspects

Volume

4

Issue

3

Pages

26-32

Abstract

Nonlinear pharmacokinetics resulting from high lipophilic and low oral bioavailability, and hypersensitivity reactions and hyperlipidemia caused by formulation by Cremophor EL have limited clinical effectiveness of paclitaxel (Taxol). In this way, there is the critical necessity of innovative drug delivery systems (DDSs) to mitigate severe side effects and overcome clinical limitations of paclitaxel. In recent years, various micro- and nanoformulations, specifically polymeric nanoparticles (NPs) and lipid NPs, have been presented and approved by the Food and Drug Administration (FDA). In addition, other nanoformulations, such as polymeric nanoparticles (NPs), micelles, liposomes, and mesoporous silica nanoparticles, have shown promising results in vitro and in vivo; however, some clinical limitations still exist, including the large-scale production and control of nanoformulation morphology. Based on the above short description, we have tried to explain advances and challenges of novel formulations of paclitaxel in both micro- and nanoscale in recent years, particularly in the year range of 2021-2025.

Rights

© 2025 by the Authors.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY 4.0) International License.

Original Publication Citation

Tayebi, L., & Alavi, M. (2025). Novel micro-and nanoformulations of paclitaxel for targeting metastatic breast, non-small cell lung, and pancreatic cancers. Micro Nano Bio Aspects, 4(3), 26-32, Article e231642. https://doi.org/10.22034/mnba.2025.540837.1153

ORCID

0000-0003-1947-5658 (Tayebi)

Download

Share

COinS